C. Mala

发表

A Measure to Study Skin Reflectance using Non-Invasive Photosensor with Economic Design

P. R. Vittal, N. Sriraam, C. Mala, 2015 .

Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison.

W. Oyen, P. D. De Mulder, E. Oosterwijk, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer

V. Heinemann, M. Ebert, S. Boeck, 2013, British Journal of Cancer.

A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma.

P. Mulders, E. Oosterwijk, S. Warnaar, 2006, The Journal of urology.

Targeting of Metastatic Renal Cell Carcinoma with the Chimeric Monoclonal Antibody G250 Labeled with 131I or 111In

W. Oyen, E. Oosterwijk, P. Mulders, 2003 .

Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma.

W. Oyen, P. D. De Mulder, E. Oosterwijk, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients

C. Lamers, P. Mulders, E. Oosterwijk, 2004, British Journal of Cancer.

A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients.

C. Lamers, P. Mulders, P. D. De Mulder, 2003, Folia biologica.

Phase II, two-arm, double-blind, multicenter, randomized study of the combination of oral WX-671 plus capecitabine versus capecitabine in first-line HER2-negative metastatic breast cancer (MBC).

F. Cardoso, N. Harbeck, L. Goldstein, 2010 .

Randomized phase II trial with an uPA inhibitor (WX-671) in patients with locally advanced nonmetastatic pancreatic cancer.

V. Heinemann, T. Pintér, M. Ebert, 2010 .

The Oral Serine Protease Inhibitor WX-671 – First Experience in Patients with Advanced Head and Neck Carcinoma

H. Graefe, B. Wollenberg, N. Rotter, 2008, Breast Care.

Radioimmunotherapy with [131I]cG250 in Patients with Metastasized Renal Cell Cancer: Dosimetric Analysis and Immunologic Response

W. Oyen, P. D. De Mulder, E. Oosterwijk, 2005, Clinical Cancer Research.

Results of a phase I/II study with monoclonal antibody CG250 in combination with IFN α-2A in metastatic renal cell carcinoma patients

P. Bevan, R. Oberneder, C. Mala, 2004 .

First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery

H. Thieme, N. Pfeiffer, M. Janicot, 2017, PloS one.

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.

J. Sludden, Y. Drew, D. Jamieson, 2016, European journal of cancer.

A Phase I pharmacokinetic and pharmacodynamic study of the oral MEK inhibitor , WX-554 , in patients with advanced solid tumours

Vicky, J. Sludden, Y. Drew, 2016 .

The Role of uPA and uPA Inhibitors in Breast Cancer

P. Bevan, C. Mala, 2008, Breast Care.

First-inhuman phase I study of ISTH 0036 , an antisense oligonucleotide selectively targeting transforming growth factor beta 2 ( TGF-β 2 ) , in subjects with open-angle glaucoma undergoing glaucoma filtration surgery

H. Thieme, N. Pfeiffer, M. Janicot, 2017 .

A randomized double-blind phase II study of the combination of oral WX-671 plus capecitabine versus capecitabine monotherapy in first-line HER2-negative metastatic breast cancer (MBC).

N. Harbeck, L. Goldstein, B. Schmalfeldt, 2013 .

Automatic substantia nigra segmentation in neuromelanin-sensitive MRI by deep neural network in patients with prodromal and manifest synucleinopathy.

R Krupička, S Mareček, C Malá, 2019, Physiological research.

Results of a phase I/II study with monoclonal antibody CG250 in combination with IFN α-2A in metastatic renal cell carcinoma patients.

P. Bevan, R. Oberneder, C. Mala, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.